Table 3.
Clinical trials of CD3+ bispecific T-cell redirectors for solid cancers.
| Targets | Clinical trial Phase | Clinical trial identifier | Disease indication(s) | Organisation(s) | Antibody |
|---|---|---|---|---|---|
| CD3 × B7-H3 | Phase 1 | NCT03406949 | Advanced solid tumours | MacroGenics | Orlotamab; MGD009 |
| CD3 × CEACAM | Phase 1 | Gastrointestinal adenocarcinoma | Amgen; MedImmune | AMG 211; MEDI-565 | |
| CD3 × CEACAM | Phase 1/2 | Colorectal cancer; NSCLC | Hoffmann-La Roche | Cibisatamab; RO6958688 | |
| CD3 × CLDN18.2 | Phase 1 | NCT04260191 | Gastric and gastro-oesophageal junction adenocarcinoma | Amgen | AMG 910 |
| CD3 × DLL3 | Phase 1 | NCT03319940 | SCLC | Amgen | AMG 757 |
| CD3 × EGFRvIII | Phase 1 | NCT03296696 | Glioblastoma | Amgen | AMG 596 |
| CD3 × EGFR | Phase 1/2 | Pancreatic cancer; colorectal cancer; glioblastoma | Barbara Ann Karmanos Cancer Institute; University of Virginia | EGFR2Bi-ATC; EGFR-BATs | |
| CD3 × EpCAM | Phase 1 | CTR20181212 | Malignant ascites | Wuhan YZY Biopharma | M701 |
| CD3 × EpCAM | Withdrawn from market | Withdrawn from market | Malignant ascites | Trion Pharma | Catumaxomab; Removab |
| CD3 × GD2 | Phase 1/2 | NCT02173093 | Neuroblastoma | University of Virginia | GD2Bi-aATC |
| CD3 × gpA33 | Phase 1/2 | Colorectal cancer | MacroGenics | MGD007 | |
| CD3 × gp100 | Phase 1/2 | Uveal melanoma; malignant melanoma | Immunocore; University of Pennsylvania | IMCgp100 | |
| CD3 × GPC3 | Phase 1 | NCT02748837 | Solid tumours | Chugai Pharmaceutical | ERY974 |
| CD3 × GUCY2c | Phase 1 | NCT04171141 | Gastrointestinal tumours; colorectal cancer; oesophageal adenocarcinomas | Pfizer | PF-07062119 |
| CD3 × HER2 | Phase 1/2 | Prostate cancer; breast cancer; leptomeningeal metastases | Barbara Ann Karmanos Cancer Institute; University of Virginia | HER2Bi-ATC; HER2-BATs | |
| CD3 × HER2 | Phase 1 | NCT03448042 | Solid tumours | Genentech | BTRC4017A |
| CD3 × HER2 | Phase 1/2 | NCT03983395 | Breast cancer | Glenmark Pharmaceuticals | GBR 1302; ISB 1302 |
| CD3 × HER2 | Phase 1 | CTR20171194 | Advanced solid tumours | Wuhan YZY Biopharma | M802 |
| CD3 × MAGE-A4 | Phase 1/2 | NCT03973333 | Advanced solid tumours | Immunocore Ltd | IMC-C103C |
| CD3 × MSLN × ALB | Phase 1/2 | NCT03872206 | Ovarian cancer; fallopian tube cancer; peritoneal cancer; pancreatic cancer; mesothelioma | Harpoon Therapeutics | HPN536 |
| CD3 × MUC1 | Phase 2 | Kidney cancer; breast cancer; lung cancer; gastric cancer; pancreatic cancer; colorectal cancer; liver cancer | Fuda Cancer Hospital, Guangzhou; Benhealth Biopharmaceutical | Activated CIK and CD3-MUC1 | |
| CD3 × MUC16 | Phase 1/2 | NCT03564340 | Ovarian cancer; fallopian tube cancer; primary peritoneal cancer | Regeneron; Sanofi | REGN4018 |
| CD3 × MUC17 | Phase 1 | NCT04117958 | Gastric and gastro-oesophageal junction cancer | Amgen | AMG 199 |
| CD3 × P-cadherin | Phase 1 | NCT02659631 | Triple-negative breast cancer; colorectal cancer; NSCLC | Pfizer | PF-06671008 |
| CD3 × PRAME | Phase 1/2 | NCT04262466 | Advanced solid tumours | Immunocore Ltd | IMC-F106C |
| CD3 × PSCA | Phase 1 | NCT03927573 | Pancreatic cancer; breast cancer; urogenital cancer; NSCLC | Celgene | GEM3PSCA |
| CD3 × PSMA | Phase 1 | NCT03926013 | Prostate cancer; renal cell carcinoma | Janssen | JNJ-63898081 |
| CD3 × PSMA | Phase 1 | NCT03792841 | Prostate cancer | Amgen | AMG 160 |
| CD3 × PSMA | Phase 1 | NCT01723475 | Prostate cancer | Amgen; Bayer | Pasotuxizumab; AMG 212 |
| CD3 × PSMA | Phase 1 | NCT02262910 | Prostate cancer | Aptevo Therapeutics | ES414 |
| CD3 × PSMA × ALB | Phase 1 | NCT03577028 | Prostate cancer | Harpoon Therapeutics | HPN424 |
| CD3 × SSTR2 | Phase 1 | NCT03411915 | Neuroendocrine tumours; gastrointestinal stromal tumours | Xencor | Tidutamab; XmAb18087 |
| CD3 × STEAP1 | Phase 1 | NCT04221542 | Prostate cancer | Amgen | AMG 509 |
| CD3 × 5T4 | Phase 1/2 | NCT04424641 | Solid tumours | Genmab; AbbVie | GEN1044 |
CEACAM carcinoembryonic antigen-related adhesion molecule, CLDN18.2 claudin-18 isoform 2, DLL3 delta-like canonical notch ligand 3, EGFRvIII epidermal growth factor receptor vIII, EGFR epidermal growth factor receptor, EpCAM epithelial cell adhesion molecule, gpA33 glycoprotein A33, gp100 glycoprotein 100, GUCY2c guanylate cyclase 2c, HER2 human epidermal growth factor receptor 2, MAGE-A4 melanoma-associated antigen A4, MSLN mesothelin, ALB albumin, MUC1 mucin 1, MUC16 mucin 16, MUC17 mucin 17, PRAME preferentially expressed antigen in melanoma, PSCA prostate stem cell antigen, PSMA prostate-specific membrane antigen, SSTR2 somatostatin receptor type 2, STEAP1 six transmembrane epithelial antigen of the prostate 1, NSCLC non-small cell lung cancer, SCLC small-cell lung cancer.